Development of Cell Selective particle irradiation using epithermal neutron beam for malignant brain tumor.

使用超热中子束进行细胞选择性粒子照射治疗恶性脑肿瘤的进展。

• 批准号: 17390390
• 负责人: MATSUMURA Akira
• 金额: $ 10.12万
• 依托单位: University of Tsukuba
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2005
• 资助国家: 日本
• 起止时间: 2005 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17390390/
• 关键词: Glioma; BNCT; Boron; Neutron; Brain Tumor; 脳腫瘍; BMCT; グリオブラストーマ

Clinical trial of BNCT for GlioblastomaEight patients with histological proven glioblastoma with an average age of 65 years (range 32-76, M:F=2:6) were underwent BNCF with new protocol which add 30Gy X ray irradiation after BNCT. 7 patients were treated with intra-operative BNCT before the protocol. In these 15 cases, 5 cases are alive; the average post BNCT follow up period was 20.3 months. Time to progression was 11.9 months, overall survival was 25.3 months. Adverse event (Grade 3>) were seen in 2 cases; convulsion and brain swelling (1 case) and transient oculomotor palsy (1 case). These result superior to standard treatments and suggest the effectiveness of the BNCT for malignant gliomaMR spectroscopyFor estimating absolute concentration of boron compounds in tissue, proton MR spectroscopy (MRS) was applied to quantify phenylalanine and L-p-boronophenylalanine (BPA). We could identify several characteristic resonances, peak of 7.32ppm (phenylalanine), four peak ranged 7.1 ppm to 7.6 ppm (BPA). A water phantom were used, and absolute concentration were obtained by proton MRS using a tissue water signal as an internal standards. These methods have high correlation between the calculated concentrations based on MRS and the known concentration. (R=0.99: phenylalanine and BPA).These clinical results appear to encouraging, but the effectiveness of the invading tumor cells are still unclear. Improved tumor targeting boron delivery and neutron distribution will enhance the therapeutic effectiveness of BNCT.MR spectroscopy results indicate that proton MRS can be non-invasive and potentially useful technique for BPA quantification in BNCT.

胶质母细胞瘤BNCT治疗的临床研究8例胶质母细胞瘤患者，年龄32-76岁，男：女=2：6，平均65岁。7例患者在方案之前接受了术中BNCT治疗。15例中5例存活，平均随访20.3个月。至进展时间为11.9个月，总生存期为25.3个月。2例出现不良事件（3级）;惊厥和脑肿胀（1例）和短暂性眼麻痹（1例）。这些结果上级优于标准治疗，表明BNCT对恶性胶质瘤的有效性。为了估计组织中硼化合物的绝对浓度，应用质子磁共振波谱（MRS）定量苯丙氨酸和L-对-硼苯丙氨酸（BPA）。我们可以识别出几个特征共振峰，峰7.32ppm（苯丙氨酸），四个峰范围为7.1 ppm至7.6 ppm（BPA）。使用水模体，并使用组织水信号作为内标通过质子MRS获得绝对浓度。这些方法在基于MRS的计算浓度与已知浓度之间具有高度相关性。（R=0.99：苯丙氨酸和BPA）。这些临床结果似乎令人鼓舞，但入侵肿瘤细胞的有效性仍不清楚。改善肿瘤靶向硼输送和中子分布将提高BNCT的治疗效果。MR波谱结果表明，质子MRS可以是无创的，潜在的有用的技术，BPA定量BNCT。

项目成果

Dosimetry for Neutron capture Therapy in JRR-4

JRR-4 中子俘获疗法的剂量测定

• 发表时间: 2007
• 期刊: Japanese Journal of Health Physics 4281
• 作者: Kumada H;Yamamoto T
• 通讯作者: Yamamoto T

Histopathological evaluation of glioblastoma after high-dose radiation therapy

高剂量放射治疗后胶质母细胞瘤的组织病理学评估

• 发表时间: 2007
• 作者: Tsurubuchi T;Yamamoto T;Enomoto T;Sato M;Sakamoto N;Matsuda M;Marushima A;Nakai K;Saito A;Shibata Y;Tsuboi K;Matsumura. A
• 通讯作者: Matsumura. A

Effects of combined treatment using sodium borocaptate(BSH) and buthionine sulfoximide(BSO) in a rat tumor model

硼己酸钠（BSH）与丁硫氨酸亚磺酰亚胺（BSO）联合治疗大鼠肿瘤模型的效果

• 发表时间: 2006
• 作者: Fumiyo Yoshida;Tetsuya Yamamoto;Kei Nakai;Yasushi Shibata;Akira Matsumura
• 通讯作者: Akira Matsumura

Proton MR spectroscopy for quantification of 1-phenylalanine

用于 1-苯丙氨酸定量的质子磁共振波谱

• 发表时间: 2007
• 作者: Yamamoto Y;Isobe T;Anno I;Yamamoto T;Shibata Y;Matsumura A
• 通讯作者: Matsumura A

Proton MR spectroscopy for quantification of l-phenylalanine

用于 L-苯丙氨酸定量的质子磁共振波谱

• 发表时间: 2007
• 作者: Yamamoto Y;Isobe T;Anno I;Yamamoto T;Shibata Y;Matsumura A.
• 通讯作者: Matsumura A.